Targeting Eukaryotic Translation Initiation Factor 4E (eIF4E) in Cancer

Andrew C. Hsieh¹,² and Davide Ruggero¹

Abstract

Recent advances in understanding the role of eukaryotic translation initiation factor 4E (eIF4E) in tumorigenesis and cancer progression have generated significant interest in therapeutic agents that indirectly or directly target aberrant activation of eIF4E in cancer. Here, we address the general function of eIF4E in translation initiation and cancer, present evidence supporting its role in cancer initiation and progression, and highlight emerging therapeutics that efficiently target hyperactivated eIF4E. In doing so, we also highlight the major differences between these therapeutics that may influence their mechanism of action. Clin Cancer Res; 16(20); 4914–20. ©2010 AACR.

Background

eIF4E and translation control

The multistep process by which ribosomes are recruited to mature mRNA sequences is a highly regulated process that requires the coordination of free 40S ribosomal subunits, mRNA, and the eukaryotic translation initiation factor 4F (eIF4F) translation initiation complex. eIF4F is a trimeric complex composed of eukaryotic translation initiation factor 4E (eIF4E), the 5′ cap mRNA-binding protein; eIF4A, an RNA helicase; and eukaryotic translation initiation factor 4G (eIF4G), a scaffolding molecule. The eIF4E protein provides the critical interface between mRNA, recruitment of eIF4A and eIF4G, and the 40S ribosomal subunit because it binds to the 7-methyl guanosine cap structure at the end of mRNAs (1, 2). eIF4E is regulated at multiple levels, including transcriptionally, by phosphorylation of serine 209, as well as through inhibitory interactions with a series of binding proteins (4EBP; Fig. 1A). The tight regulation of eIF4E availability and activity provides a rapid mechanism to modulate translation in response to hypoxia, DNA damage, nutrient availability, and oncogenic stimulation.

eIF4E binding proteins 1-3 (4EBP1-3) are a family of three small acidic proteins that compete with eIF4G to bind the dorsal surface of eIF4E. In a hypophosphorylated state, 4EBPs prevent the formation of the eIF4F complex by preventing the recruitment of eIF4G to the 5′ cap of mRNA (Fig. 1A). However, upon mitogen, growth factor, and cytokine stimulation, 4EBPs are phosphorylated at serine-threonine residues leading to a conformational alteration that releases eIF4E, allowing for binding by eIF4G. The mammalian target of rapamycin (mTOR) is the primary kinase that phosphorylates 4EBPs and serves a priming function for subsequent phosphorylations that lead to the dissociation of 4EBP from eIF4E.

eIF4E is also intrinsically regulated by phosphorylation at serine 209 by the extracellular signal-regulated kinase (ERK), and p38 MAP kinase targets MNK1 and MNK2 (3–5). The functional role of eIF4E phosphorylation is context dependent. At steady state, MNK1/MNK2 knockout mice do not exhibit any overt defects in cell growth during development (5). However, phosphorylation of serine 209 is necessary to maintain the full transforming potential of eIF4E in vitro and to potentiate MYC driven tumorigenesis in vivo (6, 7). It should be noted that in the preceding studies mutant forms of eIF4E were overexpressed. It is uncertain if endogenous eIF4E S209 phosphorylation is required for oncogenesis. In order to address this question, an eIF4E S209 knock-in mutant murine model has been generated that seems to decrease tumor-formation downstream loss of the tumor suppressor PTEN.³ Thus at this time, eIF4E phosphorylation does not seem to have a significant function in normal tissue development, but may provide a selective advantage through improved translation efficiency, which facilitates transformation in the setting of oncogenic stress.

The exact mechanism by which eIF4E and the eIF4F complex induce oncogenic transformation is hotly debated; however, it is believed to be mediated in part through enhanced translation of a subset of mRNAs involved in critical cellular processes implicated in oncogenesis such as cell proliferation, survival, and invasion.

³ N. Sonenberg, personal communication; and eIF4E phosphorylation promotes tumorigenesis and is associated with prostate cancer progression, submitted for publication.
as cell proliferation, evasion of apoptosis, angiogenesis, and metastasis (8, 9). These putative targets include cyclin D1, cyclin-dependent kinase 2 (CDK2), cMYC, Mcl-1, Bcl-2, survivin, vascular endothelial growth factor (VEGF), fibroblast growth factor 2 (FGF2), matrix metalloproteinase 9 (MMP9), and heparanase (Fig. 1B). These transcripts have long 5′ untranslated regions (5′ UTR) and high G/C contents, which result in complex hairpin structures that require the helicase activity of eIF4A to permit scanning of the 40S ribosomal subunit. These mRNAs are termed “weak” mRNA because they are poorly translated and are thought to rely more on increased eIF4E activity for their translation, thereby providing an additional barrier for tight regulation over protein expression. In the setting of oncogenic stimuli, these “weak” mRNAs are given a translational boost through the hyperactivity of eIF4E, allowing for increased eIF4F complex formation and increased eIF4A helicase activity, which results in improved translational efficiency. As a result, subsets of mRNAs that may contribute to oncogenesis are selectively activated (Fig. 1B). Many of these targets have been uncovered in cell-based eIF4E overexpression systems. However, few of these targets have been validated in more physiologically relevant in vivo cancer models, so the exact role that these putative eIF4E targets play in tumor formation and progression is uncertain. eIF4E targets may also differ between different tissue types, which adds a significant layer of complexity to our understanding of translationally controlled oncogenic networks regulated by eIF4E.

**eIF4E in cancer initiation and progression**

The oncogenic potential of eIF4E hyperactivity has been well described both in vitro and in vivo. Overexpression of eIF4E is sufficient to induce transformation of fibroblasts and primary epithelial cells (10, 11). eIF4E overexpression in vivo leads to increased cancer susceptibility; eIF4E transgenic mice develop lymphomas, angiosarcomas, lung carcinomas, and hepatomas (12). Additionally, eIF4E overexpression can overcome MYC-induced apoptosis, which shows that eIF4E possesses intrinsic oncogenic
activity that can overcome the cellular barrier of apoptosis resulting from MYC-induced oncogenic stress (12, 13). eIF4E gene amplification has been reported in human breast cancer and in head and neck cancer specimens compared with noncancerous control samples (14, 15).

Although an increase in cellular eIF4E activity is in itself oncogenic, common signaling pathways that are heavily mutated or amplified in human cancers directly impact eIF4E activity as well. For instance, the eIF4E promoter contains two E box domains that are direct targets of cMYC. cMYC overexpression drives eIF4E transcription, whereas dominant negative MYC represses eIF4E transcription (16). Our laboratory recently showed that, in the setting of oncogenic activation of the phosphoinositide 3-kinase (PI3K)/AKT/mTOR signaling pathway, phosphorylation of 4EBP1 resulting in hyperactivation of eIF4E is required for lymphomagenesis, as well as cancer progression in vivo. Interestingly, inhibition of phosphorylation of ribosomal protein S6 (rpS6; another downstream arm of mTOR) by mTOR does not decrease the rate of tumorigenesis and, thus, supports the primary role of the 4EBP1/eIF4E axis in cancer formation downstream of oncogenic mTOR (17). Activation of the oncogenic RAS– (an upstream regulator of the MNK kinase) and AKT-signaling pathways induces the formation of glioblastoma multiforme (GBM) in neural progenitor cells, which is accompanied by a dramatic upregulation in translational regulation of oncogenic networks (18). However, a critically unresolved question is whether eIF4E hyperactivation plays a direct role downstream of oncogenic MYC and RAS toward cancer progression. Downstream of oncogenic AKT, we have uncovered that blocking eIF4E hyperactivity after tumor formation in vivo results in inhibition of tumor growth (17). Taken together, eIF4E is an oncogene, as well as an important target for oncogenic translational deregulation in the context of MYC, PI3K/AKT/mTOR, and RAS overexpression (Fig. 1A). Therefore, eIF4E represents an attractive therapeutic target in human cancers because it embodies an integrating focal point downstream of these bona fide oncogenic pathways.

Clinical relevance of eIF4E in human cancers

eIF4E overexpression is common in multiple cancer types, including malignancies of the prostate, breast, stomach, colon, lung, skin, and the hematopoietic system. Increased expression of eIF4E is associated with increasing grade of disease (19–26). Furthermore, elevated total eIF4E levels along with 4EBP1 hyperphosphorylation, which increases the availability of eIF4E to bind with eIF4G and enhance cap-dependent translation, have been observed in both breast cancer and prostate cancer and correlate with both decreased progression-free and overall survival (19, 20). Deregulation of eIF4E activity is present in a large spectrum of human malignancies. As such, elevated eIF4E levels may serve as a biomarker that predicts disease progression, overall survival, or relapse after definitive therapy. This finding has been most specifically delineated in breast cancer; patients with lower eIF4E levels post neoadjuvant therapy have a significant improve-
4EBP1 is necessary for oncogenesis and tumor maintenance in AKT-driven lymphomas, whereas phosphorylation of rp56 is dispensable (17). Thus, continued activation of the 4EBP1/eIF4E axis downstream of oncogenic mTOR is the likely culprit behind the clinical failure of rapamycin and associated analogs.

In light of the clear need for more potent inhibitors of mTOR, a series of ATP-active site inhibitors of mTORC1 and mTORC2, such as PP242, Torin1, WYE-132, KU-0063794, Palomid 529, and AZD8055, were recently reported by several groups (31–36). All of these compounds target the catalytic cleft of mTOR and reversibly compete against ATP to bind the mTOR catalytic domain. Unlike allosteric inhibitors of mTOR such as rapamycin, which predominantly inhibit S6ks phosphorylation, PP242 effectively blocks the phosphorylation of all three mTOR targets, which include 4EBP1, rp56, and AKT. This results in a more significant antiproliferative effect in cultured murine and human cell lines compared with rapamycin (31). More recently, our laboratory showed, in tumors from lymphoma-prone AKT transgenic mice, that, by mutating 4EBP1 and rendering it insensitive to mTOR phosphorylation, PP242 was no longer able to induce apoptosis (17). Furthermore, it has been shown that both PP242 and Torin1 retain their antiproliferative effect in mouse embryonic fibroblasts that are unable to phosphorylate AKT at the S473 site through destabilization of the mTORC2 complex (31, 32). Thus, the antitumor effect of ATP-active site inhibitors of mTOR is mediated through inhibition of the 4EBP1/eIF4E axis, resulting in a decrease in cap-dependent translation. These findings, however, do not exclude the possibility that inhibition of S6ks and AKT phosphorylation or other targets may contribute to the antitumor efficacy of mTOR ATPactive site inhibitors in other cellular contexts.

Multiple pharmaceutical companies have ATP-active site inhibitors in their pipelines, and we suspect that many more will be tested in phase I trials in the coming years. A more potent form of PP242, INK128, is currently in phase I clinical trials in patients with advanced solid tumors as well as multiple myeloma (NIH sponsored and/or endorsed clinical trials: NCT01058707, NCT01118689). AZD2014 is also being studied for safety, tolerability, and pharmacokinetics in late-stage cancers (NCT01026402). Palomid 529 is being tested in patients with advanced neovascular age-related macular degeneration (NCT01033721). Dual PI3K/mTOR ATP-analog inhibitors are currently under clinical investigation as well (BEZ225, PF-04691502, XL765). However, given the fact that PI3K activates multiple targets, it is unlikely that the therapeutic efficacy of these dual inhibitors relies solely on inhibition of eIF4E hyperactivation. In addition, it is also possible that targeting mTOR is sufficient to induce the same anticancer effect as a dual kinase inhibitor with fewer associated toxicities.

eIF4E-eIF4G interaction inhibitor, 4EGI-1

The dorsal surface of eIF4E is a critical interface regulated by the recruitment and binding of eIF4G (Fig. 1A). Binding of eIF4G to eIF4E increases cap-dependent translation through recruitment of eIF4A and the elf3-40S ribosomal subunit. Targeting the eIF4E/eIF4G protein-protein interaction is a plausible mechanism to inhibit cap-dependent translation. eIF4G possesses a Y(X)4LF motif, in which X is variable and F is hydrophobic, which binds to conserved hydrophobic residues on the dorsal surface of eIF4E (37). It has been shown that mutations to the Y(X)4LF motif prevent the formation of the eIF4F complex. Given the conserved residues that facilitate the binding of eIF4G to the dorsal surface of eIF4E, a chemical inhibitor that targets this interaction could potentially prevent the formation of the eIF4F complex, thereby decreasing aberrant protein synthesis in the setting of eIF4E hyperactivity.

Using a high-throughput fluorescence polarization assay, in which the investigators screened chemical libraries for candidates that could displace or prevent the binding of a fluorescently labeled peptide that contained the Y(X)4LF motif from eIF4E, a candidate compound was discovered. 4EGI-1 is able to inhibit the formation of the eIF4F complex at micromolar concentrations. Given that both eIF4G and 4EBP1 possess Y(X)4LF motifs, it was hypothesized that 4EGI-1 would also inhibit the 4EBP1/eIF4E complex formation; however, this was not observed and, on the contrary, 4EGI-1 only inhibits the eIF4E/eIF4G interaction. 4EGI-1 is both a cytotoxic and cytostatic agent across multiple cell lines and, importantly, inhibits proliferation and clonogenic growth of transformed cells more significantly than untransformed cells (38, 39). The 4EGI-1 compound is licensed to Eugenix, who are working toward an Investigational New Drug application for this compound.

These findings are novel and exciting, but are tempered by several considerations. To date, it has not been shown conclusively that 4EGI-1 does not interrupt or inhibit other protein-protein interactions and, therefore, may elicit antitumor effects through more general inhibition of important oncogenic pathways. This finding is supported by the recent finding that 4EGI-1 can induce apoptosis through an eIF4G/eIF4E-independent mechanism through proteasome-mediated degradation of the antiapoptotic c-FLIP (40). In addition, micromolar amounts of 4EGI-1 are required to decrease cell proliferation and induce apoptosis, making this compound less likely to be considered for clinical use at such high concentrations. However, a forthcoming generation of increasingly potent inhibitors of the eIF4G/eIF4E protein-protein interaction may serve as a novel therapeutic approach to target eIF4E hyperactivation in cancer.

Antisense targeting of eIF4E: eIF4E antisense oligonucleotide

On the basis of the finding that elf4E is commonly elevated in multiple human malignancies and has bona fide

4 G. Wagner, personal communication.
oncogenic potential when overexpressed, direct targeting of eIF4E mRNA by specific antisense oligonucleotide (ASO) therapy has been extensively studied and is currently under investigation as a possible anticancer agent. ASOs recognize and hybridize to target mRNA and trigger RNase H-mediated RNA destruction. The efficacy of first generation ASOs was severely limited by a lack of nuclelease resistance, resulting in relatively short half-lives in vivo. However, second generation ASOs have been reengineered to improve potency, nuclelease resistance, and tissue half-life. Given the short lengths of the ASOs, they are unlikely to induce a systemic interferon response. eIF4E ASO decreases eIF4E protein levels and is cytotoxic across a panel of human cancer cell lines at nanomolar concentrations (19, 41). In a tumor xenograft model in which mice were treated with 5, 12.5, or 25 mg/kg of eIF4E-ASO three times per week, significant inhibition of tumor growth was observed without any noticeable toxicity as measured by changes in body weight and liver function tests (41). A dose-escalation phase I clinical trial is currently underway with the eIF4E ASO LY2275796 (NCT00903708). It is uncertain if eIF4E-targeted degradation will be achieved in humans; however, eIF4E levels are being ascertained in enrolled patients. These findings have important implications for our understanding of the physiologic versus oncogenic role of eIF4E. In particular, xenograft mice treated with doses of eIF4E-ASO leading to greater than 50% reduction in eIF4E levels did not show any overt toxicities, indicating that low eIF4E levels are tolerated in normal tissues. However, cancer cells, which possess increased eIF4E activity, may be more sensitive to eIF4E inhibition.

Inhibition of eIF4E phosphorylation: MNK kinase inhibitors

eIF4E phosphorylation is, theoretically, an attractive antitumor target, given the minimal effect of phosphorylation on basic cellular functions, but with a significant effect on transformation in vitro. However, chemical inhibitors of the putative kinase of eIF4E S209, MNK1/2, have shown only limited preclinical efficacy in cell-based systems. For instance, although targeted mutations of the eIF4E S209 site significantly inhibit the transforming potential of eIF4E in NIH3T3 cells, it has not been shown whether using a targeted inhibitor of MNK1/2 has a similar effect (6). Furthermore, the MNK kinase inhibitor CGP57380 has shown limited antiproliferative efficacy in human chronic myelogenous leukemia; however, it does improve the antiproliferative and apoptotic effects of imatinib when used in combination (42). Although multiple MNK kinase inhibitors are available, no clinical trials are underway, at present, to test the efficacy of these compounds in human cancer. The absence of trials is likely due to the fact that the oncogenic potential of eIF4E phosphorylation still requires rigorous validation both in vitro and in vivo. In addition, it is uncertain if the inhibition of MNK1/2 also inhibits the phosphorylation of additional downstream targets that are necessary for oncogenesis and cancer progression.

Targeting the eIF4E–5′ cap interaction

Ribavirin, an antiviral therapy, is a guanosine ribonucleoside analog that functions in part by mimicking the 5′ 7-methyl guanosine cap structure to compete with endogenous mRNAs for binding with eIF4E. It has been shown to decrease the formation of the eIF4F complex in vitro and has shown preclinical efficacy in acute myelogenous leukemia (AML) and squamous-cell carcinoma cell–based models (43). Furthermore, in a phase I dose-escalation trial with ribavirin in patients with AML, 1 complete response, 2 partial responses, and 4 patients with stable disease were reported out of 11 enrolled in the study (44). On the basis of these promising results, ribavirin is currently being studied in phase I-II clinical trials for patients with metastatic breast cancer and M4/M5 AML (NCT01056757, NCT01056523). Although these finding are significant for the clinical efficacy of ribavirin in human cancers, the specific mechanism of ribavirin as a cap-mimetic has been called into question by two independent groups (45–47). Thus, it is uncertain if the therapeutic efficacy of ribavirin is mediated primarily through inhibition of cap-dependent translation.

Future Developments and Considerations

eIF4E and translation initiation is an attractive target for anticancer therapeutics because it is a common downstream node on which multiple oncogenic signaling pathways converge. In addition to the inhibitory modalities already mentioned, other inhibitors of different components of the initiation machinery should be considered, including, for instance, Silvesterol, which inhibits the RNA helicase eIF4A leading to antitumor effects in xenograft models (48). With regards to future clinical trials with inhibitors of eIF4E, ideally, a prospective analysis of patient eIF4E status as determined by total eIF4E levels, 4EBP1 phosphorylation, and eIF4E phosphorylation should be ascertained to correlate with treatment response.

Although multiple putative mRNAs deregulated by increased eIF4E activity have been described (Fig. 1B), their impact on eIF4E-mediated cancer formation and progression is poorly understood. It is uncertain which of the aforementioned eIF4E targets may be necessary and/or sufficient for the development of cancer. In fact, it is likely that the relevant interaction among the several eIF4E targets would provide an oncogenic network that will differ dramatically depending on tumor type, tumor grade, and the presence or absence of metastasis. Therefore, a comprehensive map of mRNAs deregulated by eIF4E oncogenic activity will be imperative to elucidate the eIF4E translational signatures from patient samples that will serve as novel biomarkers or future therapeutic targets.
Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Acknowledgments

We would like to thank M. Barna, K. Tong, and A. Sher for critical discussion and reading of the manuscript.

References

36. Chresta CM, Davies BR, Hickson I, et al. AZD8055 is a potent,
selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity. Cancer Res 2010;70:288–98.


Clinical Cancer Research

Targeting Eukaryotic Translation Initiation Factor 4E (eIF4E) in Cancer

Andrew C. Hsieh and Davide Ruggero


Updated version
Access the most recent version of this article at:
doi:10.1158/1078-0432.CCR-10-0433

Cited articles
This article cites 48 articles, 23 of which you can access for free at:
http://clincancerres.aacrjournals.org/content/16/20/4914.full#ref-list-1

Citing articles
This article has been cited by 12 HighWire-hosted articles. Access the articles at:
http://clincancerres.aacrjournals.org/content/16/20/4914.full#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.